Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracey Otto

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Drugs in Dermatology : JDD|April 7, 2022
A Retrospective Study of Idiopathic Granulomatous Mastitis Treatment and OutcomesTracey Otto, Yahya Argobi, Gideon Smith, et al.
Dermatologic Clinics|May 25, 2024
Oral Psoriasis TherapiesJaBreia James, Tracey Otto, Julia Gao, et al.
Journal of the American Academy of Dermatology|May 16, 2022
Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapyMaria S Asdourian, Nishi Shah, Ted V Jacoby, et al.
Journal of the American Academy of Dermatology|February 3, 2023
Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapyMaria S Asdourian, Ted V Jacoby, Nishi Shah, et al.
Journal of the American Academy of Dermatology|June 23, 2022
Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockadeMaria S Asdourian, Nishi Shah, Ted V Jacoby, et al.
Journal of the American Academy of Dermatology|June 20, 2022
Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective studyMaria S Asdourian, Ted V Jacoby, Nishi Shah, et al.
Journal of the American Academy of Dermatology|February 22, 2023
Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanomaMichael R Stephens, Maria S Asdourian, Ted V Jacoby, et al.
Frontiers in Immunology|February 23, 2026
Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational studyStella X Chen, Bruna Galvao de O Wafae, Sydney Look-Why, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Drugs in Dermatology : JDD|April 7, 2022
A Retrospective Study of Idiopathic Granulomatous Mastitis Treatment and OutcomesTracey Otto, Yahya Argobi, Gideon Smith, et al.
Dermatologic Clinics|May 25, 2024
Oral Psoriasis TherapiesJaBreia James, Tracey Otto, Julia Gao, et al.
Journal of the American Academy of Dermatology|May 16, 2022
Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapyMaria S Asdourian, Nishi Shah, Ted V Jacoby, et al.
Journal of the American Academy of Dermatology|February 3, 2023
Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapyMaria S Asdourian, Ted V Jacoby, Nishi Shah, et al.
Journal of the American Academy of Dermatology|June 23, 2022
Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockadeMaria S Asdourian, Nishi Shah, Ted V Jacoby, et al.
Journal of the American Academy of Dermatology|June 20, 2022
Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective studyMaria S Asdourian, Ted V Jacoby, Nishi Shah, et al.
Journal of the American Academy of Dermatology|February 22, 2023
Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanomaMichael R Stephens, Maria S Asdourian, Ted V Jacoby, et al.
Frontiers in Immunology|February 23, 2026
Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational studyStella X Chen, Bruna Galvao de O Wafae, Sydney Look-Why, et al.
Pageof 1